The safety committee of the European Medicines Agency (EMA) has found that the Oxford-AstraZeneca COVID-19 vaccine can cause unusual blood clots.
However, it has maintained that the overall benefits of the injection in preventing coronavirus outweigh the risks of side effects.
The safety committee of the European Medicines Agency said there had been 18 deaths reported in its review of 62 cases of blood clots.
The cases came mainly from spontaneous reporting systems of the European Economic Area and the UK, where around 25 million people in total had received the vaccine.
The agency published its conclusion as the UK's Medicines and Healthcare products Regulatory Agency held a press conference on the same issue, five days after its weekly report confirmed at least 22 people had experienced health issues.
The EMA decision also follows a move in Germany, which last week suspended the use of the AstraZeneca vaccine in people under 60 years old.
Jamaica's Ministry of Health has been administering the AstraZeneca vaccine in its inoculation programme.